|12 Months Ended|
Dec. 31, 2019
|Segment disclosures [Abstract]|
The Company’s operations comprise a single reporting segment engaged in the research, development and commercialization of therapeutic drugs. As the operations comprise a single reporting segment, amounts disclosed in the consolidated financial statements represent those of the single reporting unit. In addition, all of the Company’s long-lived assets are located in Canada.
The following geographic information reflects revenue based on customer location.
The entire disclosure for operating segments.
Reference 1: http://www.xbrl.org/2003/role/disclosureRef